查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1675414

2025 年至 2033 年肺癌治疗市场报告（按疗法、癌症类型（非小细胞肺癌、小细胞肺癌）、配销通路和地区划分）

Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

2024IMARC Group全球肺癌治疗市场规模达到 330.61 亿美元。随着肺癌发病率的快速上升（全球吸烟和环境污染加剧了肺癌的发病率），个人化治疗（包括基于基因图谱的治疗）的进一步发展，以及疾病诊断技术的不断进步，以确保早期发现病理，推动了市场稳步增长。

肺癌治疗市场分析：

主要市场驱动因素：全球肺癌的盛行率和死亡率极高，导致肺癌治疗市场需求旺盛。

主要市场趋势：随着越来越多针对肿瘤细胞特定基因突变的治疗方法的出现，市场将朝着个人化医疗的方向发展。此外，在诊断过程中加入人工智慧和机器学习，可以提高获得此类治疗的机会和准确性，这是肺癌治疗市场的主要趋势之一。

地理趋势：市场分析表明，由于强大的医疗保健结构、医疗支出以及早期使用先进的肿瘤治疗方法，北美在肺癌治疗市场中处于领先地位。包括中国和印度在内的亚太地区正凭藉快速增长的医疗保健意识和不断改善的医疗保健服务系统推动市场发展。

竞争格局：根据肺癌治疗市场概况，由于知名製药巨头和新兴生物公司的存在，市场竞争激烈。此外，各大公司正在透过研发和合作来创新和扩大其产品线。

挑战与机会：新型抗癌药物的高成本成为肺癌治疗向中低收入经济体推广的主要挑战，造成了药物可近性的差距。然而，随着肺癌治疗市场近期出现开发具有成本效益的仿製药和生物相似药的机会，这些挑战也随之加剧。

肺癌治疗市场趋势：

全球肺癌发生率上升

推动肺癌治疗市场成长的另一个因素是肺癌发生率的增加。美国癌症协会对2024年美国肺癌的预测是，新发癌症人数约为234,580人，其中男性116,310人，女性118,270人。死亡人数将达125,070人，其中男性死亡65,790人，女性死亡59,280人。全球人口呈指数级增长，吸烟、空气和环境污染以及有害的工作场所事件等导致肺癌的有害因素的普遍存在，都证明了这一点。因此，这也影响了肺癌治疗市场的统计数据。由于肺癌发生率不断上升，需要采取更积极的措施。因此，肺癌治疗方法，包括药物的开发和改进也在不断发展。供应的增加为製药公司进行了测试、开发新产品并扩大产品类型提供了更多理由。因此，对更有效药物的需求日益增长。因此，肺癌治疗是成长最快的。

个人化医疗的创新

随着根据基因特征对每位患者进行治疗的个人化医疗的发展，肺癌治疗市场增长显着。近年来，製药业已经开发并生产出精准攻击此类突变的药物。事实证明，这些疗法比化疗更有效，副作用更少。肺癌治疗市场预测显示个人化医疗将成为该肿瘤治疗的基础；这意味着治疗效率的提高，因为处方将更加准确。此外，诊断技术的进步和对影响肺癌进展的遗传因素的了解不断加深，推动了人们对精准医疗的日益重视。因此，製药业对个人化解决方案的投资不断扩大，使药物开发与特定患者的需求相结合，并大大推动肺癌治疗市场的发展。

诊断和治疗不断进步

技术创新推动市场发展，特别是在诊断和治疗领域。此外，改进的影像和人工智慧辅助诊断工具可以更早、更准确地发现肺癌。除此之外，这项理念也将彻底改变治疗效果和患者復原。除此之外，肺癌治疗市场最近的发展包括引入新的和正在发展的微创手术技术、增强的放射治疗方法和先进的药物传输系统，包括基于奈米粒子的化疗製剂。此外，先进技术的准确性和有效性无法想像舒适的治疗和可恢復的患者视野。此外，所有这些技术的结合正在创造积极的市场前景。

肺癌治疗市场细分：

治疗性分手：

  • 标靶治疗
  • 贝伐单抗
  • 达拉非尼/曲美替尼
  • 盐酸厄洛替尼
  • 奥希替尼
  • 其他的
  • 免疫疗法
  • 度伐利尤单抗
  • 纳武单抗
  • 阿替利珠单抗
  • 帕博利珠单抗
  • 放射治疗
  • 外部光束
  • 内部樑
  • 系统性
  • 化疗

标靶治疗占据大部分市场份额

由于与传统化疗相比，治疗效率更高、副作用更少，因此是最大的细分市场。其中包括能够准确识别和杀死癌细胞的药物或其他物质。这种治疗方法可能针对的是区分癌细胞与其他细胞的分子和遗传特征。此外，目前对肺癌遗传的理解程度使得我们能够识别许多特定的分子靶点，并相应地识别出可以阻止这些标靶活化的药剂。根据肺癌治疗市场预测，分子生物学和遗传学的发展将不断增加可用于对抗疾病的标靶和药物的数量。因此，可以合理地假设，由于新的潜在标靶和药物的出现，标靶治疗领域将继续发展。

癌症分手类型：

  • 非小细胞肺癌（NSCLC）
  • 小细胞肺癌 (SCLC)

非小细胞肺癌（NSCLC）占据业界最大份额

非小细胞肺癌因其发病率高而占据市场最大份额。各个亚型单独来看具有共同的病理变异，但它们的进展比小细胞肺癌慢。因此，全球 NSCLC 的高盛行率使得不同亚型的肺癌治疗市场需求庞大，从而激励製药公司和研究人员专注于开发能够有效治疗亚型基因和分子差异的疗法和免疫疗法。此外，NSCLC分子发病机制不断变化也确保了精准医疗的发展使NSCLC与市场具有相关性。

依配销通路分类：

  • 医院药房
  • 零售药局
  • 网路药局
  • 其他

医院药房是主要的细分市场

由于肺癌治疗的复杂性和先进性，医院药局是肺癌治疗领域最大的通路。医生需要在受控环境中进行治疗，包括化疗方案，这些治疗需要严格调控以避免副作用。根据肺癌治疗市场分析，大多数肺癌治疗都是针对住院患者，因为需要化疗、标靶治疗和免疫疗法等复杂疗法。此外，医院药局对于促进肺癌综合治疗至关重要，因为患者可以立即获得所有所需的治疗，并且在同一家可以协调肿瘤科、外科和放射科的医院获得治疗。除此之外，中心化的集中化确保患者在接受治疗时延迟最少，进而提高治疗的效果。此外，对基础设施和人员专业知识的需求正在增加肺癌治疗市场的收入。

按地区划分：

  • 北美洲
  • 美国
  • 加拿大
  • 亚太
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲
  • 印尼
  • 其他的
  • 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他的
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他的
  • 中东和非洲

北美引领市场，占据肺癌治疗药物最大的市场份额

该报告还对所有主要区域市场进行了全面的分析，包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。根据报告，北美是肺癌治疗最大的区域市场。

由于疾病盛行率高、医疗保健基础设施先进以及医疗保健支出最高的因素之一，北美拥有最大的区域肺癌治疗市场份额。除此之外，美国和欧元区国家在研发上投入的高额政府投入和私部门支持也在北美市场的成长中扮演关键角色。此外，对开发肺癌诊断和治疗技术和措施的投资不断加速，对肺癌治疗市场的收入产生了积极影响。正如肺癌治疗市场的成长趋势所示，在过去的十年中，各种标靶疗法和免疫疗法已经被开发并用于治疗肺癌。此外，该地区的监管环境也对抗癌药物采取了快速审批的友善政策。此外，该地区患者的高认知度和保险覆盖率确保北美继续主导全球市场。

竞争格局：

市场研究报告也对市场竞争格局进行了全面的分析。也提供了所有主要公司的详细资料。肺癌治疗行业的一些主要市场参与者包括：

  • 艾伯维公司（AbbVie Inc.）
  • 安进公司
  • 阿斯特捷利康公司
  • 勃林格殷格翰国际股份有限公司
  • 百时美施贵宝公司
  • 第一三共株式会社
  • 礼来公司
  • 葛兰素史克公司
  • 默克公司
  • 诺华公司
  • 辉瑞公司
  • 罗氏控股公司
  • 武田药品工业株式会社

本报告回答的关键问题：

  • 全球肺癌治疗市场迄今表现如何？
  • 全球肺癌治疗市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球肺癌治疗市场有何影响？
  • 主要的区域市场有哪些？
  • 哪些国家拥有最具吸引力的肺癌治疗市场？
  • 根据治疗方法，市场区隔如何？
  • 肺癌治疗市面上哪种疗法最具吸引力？
  • 根据癌症类型，市场分布如何？
  • 肺癌治疗市场上最具吸引力的癌症类型是哪一种？
  • 根据配销通路，市场如何划分？
  • 肺癌治疗市场中最具吸引力的配销通路是哪一个？
  • 市场的竞争格局是怎么样的？
  • 全球肺癌治疗市场的关键参与者/公司有哪些？

本报告回答的关键问题：

  • 全球肺癌治疗市场迄今表现如何？
  • 全球肺癌治疗市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球肺癌治疗市场有何影响？
  • 主要的区域市场有哪些？
  • 哪些国家拥有最具吸引力的肺癌治疗市场？
  • 根据治疗方法，市场区隔如何？
  • 肺癌治疗市面上哪种疗法最具吸引力？
  • 根据癌症类型，市场分布如何？
  • 肺癌治疗市场上最具吸引力的癌症类型是哪一种？
  • 根据配销通路，市场如何划分？
  • 肺癌治疗市场中最具吸引力的配销通路是哪一个？
  • 市场的竞争格局是怎么样的？
  • 全球肺癌治疗市场的关键参与者/公司有哪些？

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第五章：全球肺癌治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依疗法

  • 标靶治疗
    • 关键部分
      • 贝伐单抗
      • 达拉非尼/曲美替尼
      • 盐酸厄洛替尼
      • 奥希替尼
      • 其他的
  • 免疫疗法
    • 关键部分
      • 度伐利尤单抗
      • 纳武单抗
      • 阿替利珠单抗
      • 帕博利珠单抗
  • 放射治疗
    • 关键部分
      • 外部光束
      • 内部樑
      • 系统性
  • 化疗

第 7 章：市场区隔：按癌症类型

  • 非小细胞肺癌（NSCLC）
  • 小细胞肺癌 (SCLC)

第 8 章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 10 章：驱动因素、限制因素与机会

  • 概述
  • 驱动程式
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Eli Lilly and Company
    • GSK PLC
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Roche Holding AG
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A8336

The global lung cancer therapeutics market size reached USD 33,061.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 72,610.7 Million by 2033, exhibiting a growth rate (CAGR) of 9.14% during 2025-2033. The market is experiencing steady growth driven by the rapid increase in the incidence of lung cancer, which is aggravated by smoking and environmental pollution around the world, the further development of individualized treatment, including based on the gene profile, and the continuous advancement of technology for diagnosing the disease, to ensure early detection of the pathology.

Lung Cancer Therapeutics Market Analysis:

Major Market Drivers: The massive prevalence and mortality associated with lung cancer worldwide is creating a high lung cancer therapeutics market demand.

Key Market Trends: The market will develop in the direction of personalized medicine as an increasing number of therapies addressing particular genetic mutations in tumor cells are created. Additionally, the incorporation of AI and machine learning in the diagnostic processes enhancing the chances and precision of accessing such treatments is acting as one of the major lung cancer therapeutics market trends.

Geographical Trends: The market analysis states that North America leads the market regarding lung cancer therapeutics due to the robust healthcare structures, health expenditures, and early use of advanced oncology treatments. Asia Pacific region, including China and India, is driving the market based on rapidly growing healthcare awareness and improved healthcare delivery systems.

Competitive Landscape: According to the lung cancer therapeutics market overview, the market is highly competitive based on the existence of well-established pharmaceutical giants and new emerging biofirms. Additionally, major companies are innovating and expanding their product lines through research and development and partnerships.

Challenges and Opportunities: The high cost of new cancer medicines emerges as the main challenge to the lung cancer therapeutics revelations to the low- and middle-income economies, creating accessibility gaps. However, such challenges amplify as lung cancer therapeutics market recent opportunities for developing cost-effective generics and biosimilars.

Lung Cancer Therapeutics Market Trends:

Rising incidence of lung cancer worldwide

Another factor contributing to the lung cancer therapeutics market growth is the increasing incidence of lung cancer. The American Cancer Society made an estimation of lung cancer in the US by 2024. The number of new cancer occurrences should approximately equal 234,580 individuals, including 116,310 males and 118,270 females. The number of deaths will equal 125,070 deaths, which involves 65,790 male deaths and 59,280 female deaths. This can be supported by the exponentially growing global population and the prevalence of harmful factors causing lung cancer such as smoking, air and environmental pollution, and harmful workplace events. Thus, this is also influencing the lung cancer therapeutics market statistics. Due to the constantly increasing incidence of lung cancer, more active measures are needed. Accordingly, the development and improvement of methods, including drugs, for lung cancer treatment are constantly developing. Increased supply creates more reason for pharmaceutical companies to conduct tests and develop new ones and expand their assortment. Accordingly, demand for more effective drugs is growing. Thus, lung cancer therapeutics is the fastest-growing.

Innovations in personalized medicine

The lung cancer therapeutics market growth is increasing significantly with the development of personalized medicine, which treats each patient based on genetic features. In recent years, the drug industry has developed and produced drugs that precisely attack such mutations. These have proven to be more effective than chemotherapy, causing fewer side effects. The lung cancer therapeutics market forecast suggests that personalized medicine will become the basis of therapy for this oncology; this means an increase in the efficiency of therapy since the prescription will be more accurate. Furthermore, the growing emphasis on precision medicine is fueled by technological progress in diagnostics and an increased understanding of genetic factors influencing lung cancer progression. Consequently, the pharmaceutical industry's investment in personalized solutions continues to expand, aligning drug development with specific patient needs and substantially driving the lung cancer therapeutics market forward.

Continuous advancements in diagnostics and treatment

Technological innovations drive the market, particularly in diagnostics and treatment delivery. In addition, improved imaging and AI-assisted diagnostic tools allow lung cancer detection early and more accurately. Along with this, this notion is a game-changer for treatment efficacy and patient recovery. Apart from this, the lung cancer therapeutics market recent developments include the introduction of new and developing minimally invasive surgery techniques, enhanced radiation treatment approaches, and advanced drug-delivery systems, including nanoparticle-based chemo preparations. In addition, the accuracy and effectiveness of advanced technology cannot imagine a comfortable treatment and recoverable patient view. Furthermore, the combination of all these technologies is creating a positive market outlook.

Lung Cancer Therapeutics Market Segmentation:

Breakup by Therapy:

  • Targeted Therapy
  • Bevacizumab
  • Dabrafenib/Trametinib
  • Erlotinib Hydrochloride
  • Osimertinib
  • Others
  • Immunotherapy
  • Durvalumab
  • Nivolumab
  • Atezolizumab
  • Pembrolizumab
  • Radiation Therapy
  • External Beam
  • Internal Beam
  • Systemic
  • Chemotherapy

Targeted therapy accounts for the majority of the market share

The therapy segment is the largest as it is more efficient and has fewer side effects compared to traditional chemotherapy. It includes drugs or other materials that can accurately recognize and kill cancer cells. This treatment is probably directed at the molecular and genetic features that differentiate cancer cells from others. In addition, the current level of understanding of genetic aspects of lung cancer allows the identification of many specific molecular targets and, correspondingly, agents that can prevent the activation of these targets. According to the lung cancer therapeutics market forecast, the development of molecular biology and genetics will consistently increase the number of targets and agents that could be used to combat the described disease. Hence, it is reasonable to suppose that the targeted therapy segment will continue developing due to the appearance of new potential targets and agents.

Breakup by Cancer Type:

  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)

Non-Small Cell Lung Cancer (NSCLC) holds the largest share of the industry

The non-small cell lung cancer segment holds the largest share in the market due to its high prevalence. Individually, the subtypes share pathological variations, but they progress more slowly than small-cell lung cancer. As such, the high global prevalence of NSCLC creates a sizable lung cancer therapeutics market demand for the different subtypes, thereby incentivizing pharmaceutical companies and researchers to focus on developing therapies and immunotherapies that can treat the subtype gene and molecular distinctions effectively. In addition, the changing molecular pathogenesis capacity for NSCLC also ensures that the development of precision medicine causes NSCLC to have a correlation with the market.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other

Hospital pharmacies represents the leading market segment

Hospital pharmacies are the largest channel of distribution in the lung cancer therapeutics segment due to the complicated and advanced nature of the therapies for the disease. Doctors require a controlled environment to administer treatments, including chemotherapy solutions, which need to be carefully regulated to avoid side effects. According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies. Additionally, hospital pharmacies are critical in facilitating integrated lung cancer care as the patient can access all the required treatments immediately and from the same hospital that can coordinate oncology, surgery, and radiology departments. Apart from this, the centralization of centrality ensures the patient undergoes therapy with minimal delays which improves the effectiveness of the therapeutics. Furthermore, the demand for infrastructure and personnel expertise is increasing the lung cancer therapeutics market revenue.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest lung cancer therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for lung cancer therapeutics.

North America has the largest regional lung cancer therapeutics market share due to high disease prevalence, advanced healthcare infrastructure, and one of the highest healthcare spender factors. Along with this, high government contribution and private sector support in the US and Eurozone countries, spent on research and development, also play a key role in the growth of the North American market. Furthermore, the accelerating investments to develop technologies and initiatives to diagnose and treat lung cancer are influencing lung cancer therapeutics market revenue positively. As the lung cancer therapeutics market growth trend shows, in the past decade, various targeted therapies and immunotherapies have been developed and used in the treatment of lung cancer. Furthermore, the regulatory environment across the region also has a friendly policy of fast-track cancer drugs. Moreover, the high levels of patient awareness across the region, and insurance coverage ensures North America continues to dictate the global market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the lung cancer therapeutics industry include:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • GSK PLC
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited

Key Questions Answered in This Report:

  • How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive lung cancer therapeutics market?
  • What is the breakup of the market based on the therapy?
  • Which is the most attractive therapy in the lung cancer therapeutics market?
  • What is the breakup of the market based on the cancer type?
  • Which is the most attractive cancer type in the lung cancer therapeutics market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the lung cancer therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global lung cancer therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Lung Cancer Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Targeted Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Bevacizumab
      • 6.1.2.2 Dabrafenib/Trametinib
      • 6.1.2.3 Erlotinib Hydrochloride
      • 6.1.2.4 Osimertinib
      • 6.1.2.4 Others
    • 6.1.2 Market Forecast
  • 6.2 Immunotherapy
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Durvalumab
      • 6.2.2.2 Nivolumab
      • 6.2.2.3 Atezolizumab
      • 6.2.2.4 Pembrolizumab
    • 6.2.2 Market Forecast
  • 6.3 Radiation Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Key Segment
      • 6.3.2.1 External Beam
      • 6.3.2.2 Internal Beam
      • 6.3.2.3 Systemic
    • 6.3.2 Market Forecast
  • 6.4 Chemotherapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Cancer Type

  • 7.1 Non-small Cell Lung Cancer (NSCLC)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Cell Lung Cancer (SCLC)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Boehringer Ingelheim International GmbH
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Bristol-Myers Squibb Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Daiichi Sankyo Company Limited
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Eli Lilly and Company
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 GSK PLC
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Merck & Co. Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Pfizer Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Roche Holding AG
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
    • 14.3.13 Takeda Pharmaceutical Company Limited
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Lung Cancer Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Lung Cancer Therapeutics Market: Breakup by Therapy (in %), 2024
  • Figure 5: Global: Lung Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2024
  • Figure 6: Global: Lung Cancer Therapeutics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Lung Cancer Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Lung Cancer Therapeutics (Targeted Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Lung Cancer Therapeutics (Targeted Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Lung Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Lung Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Lung Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Lung Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Lung Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Lung Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Lung Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Lung Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Lung Cancer Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Lung Cancer Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Lung Cancer Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Lung Cancer Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Lung Cancer Therapeutics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
  • Table 3: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million USD), 2025-2033
  • Table 4: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Lung Cancer Therapeutics Market: Competitive Structure
  • Table 7: Global: Lung Cancer Therapeutics Market: Key Players